Cancer BiologybioRxiv
Therapeutic targeting of SLC6A8 creatine transporter inhibits KRAS mutant and wildtype colon cancer and modulates human creatine levels
I. Kurth, N. Yamaguchi, C. Andreu-Agullo…·S. F. Tavazoie
RGX-202 inhibits CRC growth by targeting SLC6A8 creatine transporter, reduces creatine and ATP levels, and shows efficacy in multiple tumor models and human trials.